Problems and prospects for the use of stem cells in transplantation

Abstract

The problems of organ and tissue transplantation are the lack of organs for transplantation and the rejection of transplants. Therefore, the issue of obtaining organs and tissues for transplantation with stem cells is being studied. Although this idea is promising, it is associated with many problems. To do this, you need to use several populations of cells on a substrate with a complex composition of nutrient environments: nutrients, growth factors, oxygen, regulatory factors. Intercellular interaction is provided by the factors they secrete, or it occurs directly with intercellular contact. This contributes to the fact that stem cells in test tubes can differentiate into other types of tissues and maintain their biological activity indefinitely, which they cannot in vivo. This approach of tissue engineering provides the possibility of obtaining whole organs for implantation. However, technical problems are associated with increased cell adhesion to plastic, the presence of a universal basis for cell nutrition, which can contain more than 100 components. There is a possibility of contamination, which can lead to serious errors in the experiment. Stem cells must have distinct mutational properties and the ability to restore telome cells. Prolonged use of the same nutrient medium can lead to genetic changes and significantly alter the physiological properties of cells. Cryopreservation can be an important aspect of the solution. The goal of tissue bioengineering is to create whole artificial organs, or at least areas of organized tissue that could be transplanted to patients. Currently, such operations are relatively simple for tissues such as artificial skin consisting of epidermal and fibroblast layers, or small cartilage implants obtained in vitro. Several cell types in stable shape are planned to be used in one environment. In this case, one type of cell can be replaced by another. This stability is provided by a variety of secreted factors by different types of cells that ensure their vitality. Decellularization removes all components involved in immune rejection of grafts, so this raises the prospect of creating an unlimited supply of organs for transplantation. However, acute reactions can develop associated with the participation of dendritic cells, macrophages, neutrophils, natural killers. Starting from the moment of transplantation, conditions for immune rejection are created, arising as a result of surgery with the development of acute inflammation. The intensity of immune reactions against the graft largely depends on the degree of non-conformity of alleles of the main complex of histocompany capacity of the donor and recipient. This match is studied using a variety of methods, including the use of antibodies or sequencing of deoxyribonucleic acid.

Keywords

cellular differentiation / chromosome / genes / modification / mutation / nucleic acids / phenotype / plasmids / promoter / site / stem cells / transcriptional factors / translocation

References

[1] Moskalev AV, Sboichakov VB, Rudoi AS. Obschaya immunologia s osnovami klinicheskoi immunologii. Moscow: Geotar-Mеdia; 2015. (In Russ.).

[2] Москалев А.В., Сбойчаков В.Б., Рудой А.С. Общая иммунология с основами клинической иммунологии. М.: Гэотар-Медиа, 2015.

[3] Yarilin AA. Immunologia. Moscow: Geotar-Media; 2010. (In Russ.).

[4] Ярилин А.А. Иммунология. М.: Гэотар-Медиа, 2010.

[5] Abbas AK, Lichtman AN, Pillai S. Cellular and molecular immunology. 9-th edition. Philadelphia, Pennsylvania: WB Saunders Company; 2018.

[6] Abbas A.K., Lichtman A.N., Pillai S. Cellular and molecular immunology. 9-th edition. Philadelphia, Pennsylvania: W.B. Saunders Company, 2018.

[7] Bhaya D, Davison M, Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet. 2011;45:273–297. DOI: 10.1146/annurev-genet-110410-132430

[8] Bhaya D., Davison M., Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation // Annu. Rev. Genet. 2011. Vol. 45. P. 273–297. DOI: 10.1146/annurev-genet-110410-132430

[9] Cai L, Johnstone BH, Cook TG, et al. Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells. 2007;25(12):3234–3243. DOI: 10.1634/stemcells.2007-0388

[10] Cai L., Johnstone B.H., Cook T.G., et al. Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization // Stem. Cells. 2007. Vol. 25. No. 12. P. 3234–3243. DOI: 10.1634/stemcells.2007-0388

[11] Hilton IB, D’Ippolito AM, Vockley CM, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol. 2015;33(5):510–517. DOI: 10.1038/nbt.3199

[12] Hilton I.B., D’Ippolito A.M., Vockley C.M., et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers // Nat. Biotechnol. 2015. Vol. 33. No. 5. P. 510–517. DOI: 10.1038/nbt.3199

[13] Gilbert LA, Larson MH, Morsut L, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442–451. DOI: 10.1016/j.cell.2013.06.044

[14] Gilbert L.A., Larson M.H., Morsut L., et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes // Cell. 2013. Vol. 154. No. 2. P. 442–451. DOI: 10.1016/j.cell.2013.06.044

[15] Geraghty RJ, Capes-Davis A, Davis JM, et al. Cancer Research UK. Guidelines for the use of cell lines in biomedical research. Br J Cancer. 2014;111(6):1021–1046. DOI: 10.1038/bjc.2014.166

[16] Geraghty R.J., Capes-Davis A., Davis J.M., et al. Cancer Research UK. Guidelines for the use of cell lines in biomedical research // Br. J. Cancer. 2014. Vol. 111. No. 6. P. 1021–1046. DOI: 10.1038/bjc.2014.166

[17] Gjorevski N, Ranga A, Lutolf MP. Bioengineering approaches to guide stem cell-based organogenesis. Development. 2014;141(9):1794–1804. DOI: 10.1242/dev.101048

[18] Gjorevski N., Ranga A., Lutolf M.P. Bioengineering approaches to guide stem cell-based organogenesis // Development. 2014. Vol. 141. No. 9. P. 1794–1804. DOI: 10.1242/dev.101048

[19] Kang HW, Lee SJ, Ko IK, et al. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol. 2016;34(3):312–319. DOI: 10.1038/nbt.3413

[20] Kang H.W., Lee S.J., Ko I.K., et al. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity // Nat. Biotechnol. 2016. Vol. 34. No. 3. P. 312–319. DOI: 10.1038/nbt.3413

[21] Kern S, Eichler H, Stoeve J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24(5):1294–1301. DOI: 10.1634/stemcells.2005-0342

[22] Kern S., Eichler H., Stoeve J., et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue // Stem. Cells. 2006. Vol. 24. No. 5. P. 1294–1301. DOI: 10.1634/stemcells.2005-0342

[23] Lee JH, Kemp DM. Human adipose-derived stem cells display myogenic potential and perturbed function in hypoxic conditions. Biochem Biophys Res Commun. 2006;341(3):882–888. DOI: 10.1016/j.bbrc.2006.01.038

[24] Lee J.H., Kemp D.M. Human adipose-derived stem cells display myogenic potential and perturbed function in hypoxic conditions // Biochem. Biophys. Res. Commun. 2006. Vol. 341. No. 3. P. 882–888. DOI: 10.1016/j.bbrc.2006.01.038

[25] Li B, Zeng Q, Wang H, et al. Adipose tissue stromal cells transplantation in rats of acute myocardial infarction. Coron Artery Dis. 2007;18(3):221–227. DOI: 10.1097/MCA.0b013e32801235da

[26] Li B., Zeng Q., Wang H., et al. Adipose tissue stromal cells transplantation in rats of acute myocardial infarction // Coron. Artery. Dis. 2007. Vol. 18. No. 3. P. 221–227. DOI: 10.1097/MCA.0b013e32801235da

[27] Liu N, Zang R, Yang ST, et al. Stem cell engineering in bioreactors for large-scale bioprocessing. Engineering in Life Sciences. 2014;14:4–15. DOI: 10.1002/elsc.201300013

[28] Liu N., Zang R., Yang S.T., et al. Stem cell engineering in bioreactors for large-scale bioprocessing // Engineering in Life Sciences. 2014. Vol. 14. P. 4–15. DOI: 10.1002/elsc.201300013

[29] McDonald JI, Celik H, Rois LE, et al. Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation. Biol Open. 2016;5(6):866–874. DOI: 10.1242/bio.019067

[30] McDonald J.I., Celik H., Rois L.E., et al. Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation // Biol. Open. 2016. Vol. 5. No. 6. P. 866–874. DOI: 10.1242/bio.019067

[31] Olson K, De Nardin E. Contemporary clinical immunology and serology. New Jersey: Upper Saddle River; 2013.

[32] Olson K., De Nardin E. Contemporary clinical immunology and serology. New Jersey: Upper Saddle River, 2013.

[33] Rose NR, Mackay IR. The autoimmune diseases. 5th edition. Philadelphia; 2018.

[34] Rose N.R., Mackay I.R. The autoimmune diseases. 5th edition. Philadelphia, 2018.

[35] Slack JMW. The science of stem cells. Wiley; 2018.

[36] Slack J.M.W. The science of stem cells. Wiley, 2018.

[37] Sasai Y. Next-generation regenerative medicine: organogenesis from stem cells in 3D culture. Cell Stem Cell. 2013;12(5):520–530. DOI: 10.1016/j.stem.2013.04.009

[38] Sasai Y. Next-generation regenerative medicine: organogenesis from stem cells in 3D culture // Cell. Stem. Cell. 2013. Vol. 12. No. 5. P. 520–530. DOI: 10.1016/j.stem.2013.04.009

[39] Sternberg SH, Redding S, Jinek M, et al. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature. 2014;507(7490):62–67. DOI: 10.1038/nature13011

[40] Sternberg S.H., Redding S., Jinek M., et al. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9 // Nature. 2014. Vol. 507. No. 7490. P. 62–67. DOI: 10.1038/nature13011

[41] Thakore PI, D’Ippolito AM, Song L, et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods. 2015;12(12):1143–1149. DOI: 10.1038/nmeth.3630

[42] Thakore P.I., D’Ippolito A.M., Song L., et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements // Nat. Methods. 2015. Vol. 12. No. 12. P. 1143–1149. DOI: 10.1038/nmeth.3630

[43] Wu Y, Chen L, Scott PG, et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25(10):2648–2659. DOI: 10.1634/stemcells.2007-0226

[44] Wu Y., Chen L., Scott P.G., et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis // Stem. Cells. 2007. Vol. 25. No. 10. P. 2648–2659. DOI: 10.1634/stemcells.2007-0226

[45] Zabriskie JB. Essential clinical immunology. NY; 2009.

[46] Zabriskie J.B. Essential clinical immunology. N.Y., 2009.

[47] Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163(3):759–771. DOI: 10.1016/j.cell.2015.09.038

[48] Zetsche B., Gootenberg J.S., Abudayyeh O.O., et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system // Cell. 2015. Vol. 163. No. 3. P. 759–771. DOI: 10.1016/j.cell.2015.09.038

[49] Zia S, Mozafari M, Natasha G, et al. Hearts beating through decellularized scaffolds: whole-organ engineering for cardiac regeneration and transplantation. Crit Rev Biotechnol. 2016;36(4):705–715. DOI: 10.3109/07388551.2015.1007495

[50] Zia S., Mozafari M., Natasha G., et al. Hearts beating through decellularized scaffolds: whole-organ engineering for cardiac regeneration and transplantation // Crit. Rev. Biotechnol. 2016. Vol. 36. No. 4. P. 705–715. DOI: 10.3109/07388551.2015.1007495

RIGHTS & PERMISSIONS

Moskalev A.V., Gumilevsky B.Y., Apchel V.Y., Cygan V.N.